CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 514824-515237 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T63691","span":{"begin":0,"end":413},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In 3 separate clinical studies, the effects of CIC (HFA; 320-1280 μg daily) and placebo (PBO), via metered-dose inhaler (ex-actuator doses), over 9 days, 4 or 12 weeks, on basal HPA axis function (24-hour area-under-the-curve [AUC0-24h] serum or urinary cortisol corrected for creatinine) or stimulated (low-dose [1 μg] cosyntropin) serum cortisol were investigated in patients ( 18 years) with persistent asthma."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T221","span":{"begin":0,"end":413},"obj":"Sentence"}],"text":"In 3 separate clinical studies, the effects of CIC (HFA; 320-1280 μg daily) and placebo (PBO), via metered-dose inhaler (ex-actuator doses), over 9 days, 4 or 12 weeks, on basal HPA axis function (24-hour area-under-the-curve [AUC0-24h] serum or urinary cortisol corrected for creatinine) or stimulated (low-dose [1 μg] cosyntropin) serum cortisol were investigated in patients ( 18 years) with persistent asthma."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T4977","span":{"begin":52,"end":55},"obj":"Disease"},{"id":"T4978","span":{"begin":406,"end":412},"obj":"Disease"}],"attributes":[{"id":"A4977","pred":"mondo_id","subj":"T4977","obj":"http://purl.obolibrary.org/obo/MONDO_0007710"},{"id":"A4978","pred":"mondo_id","subj":"T4978","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"}],"text":"In 3 separate clinical studies, the effects of CIC (HFA; 320-1280 μg daily) and placebo (PBO), via metered-dose inhaler (ex-actuator doses), over 9 days, 4 or 12 weeks, on basal HPA axis function (24-hour area-under-the-curve [AUC0-24h] serum or urinary cortisol corrected for creatinine) or stimulated (low-dose [1 μg] cosyntropin) serum cortisol were investigated in patients ( 18 years) with persistent asthma."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T2751","span":{"begin":406,"end":412},"obj":"Phenotype"}],"attributes":[{"id":"A2751","pred":"hp_id","subj":"T2751","obj":"http://purl.obolibrary.org/obo/HP_0002099"}],"text":"In 3 separate clinical studies, the effects of CIC (HFA; 320-1280 μg daily) and placebo (PBO), via metered-dose inhaler (ex-actuator doses), over 9 days, 4 or 12 weeks, on basal HPA axis function (24-hour area-under-the-curve [AUC0-24h] serum or urinary cortisol corrected for creatinine) or stimulated (low-dose [1 μg] cosyntropin) serum cortisol were investigated in patients ( 18 years) with persistent asthma."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T1082","span":{"begin":237,"end":242},"obj":"Body_part"},{"id":"T1083","span":{"begin":333,"end":338},"obj":"Body_part"}],"attributes":[{"id":"A1082","pred":"uberon_id","subj":"T1082","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A1083","pred":"uberon_id","subj":"T1083","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"In 3 separate clinical studies, the effects of CIC (HFA; 320-1280 μg daily) and placebo (PBO), via metered-dose inhaler (ex-actuator doses), over 9 days, 4 or 12 weeks, on basal HPA axis function (24-hour area-under-the-curve [AUC0-24h] serum or urinary cortisol corrected for creatinine) or stimulated (low-dose [1 μg] cosyntropin) serum cortisol were investigated in patients ( 18 years) with persistent asthma."}